Takeda’s oral orexin receptor 2-selective agonist oveporexton met all primary and secondary endpoints in two phase III studies for narcolepsy type 1, demonstrating clinically meaningful improvements in wakefulness and related symptoms. The drug was generally well tolerated with a consistent safety profile. Takeda plans to file for regulatory approval within the current fiscal year, positioning oveporexton to become the first-in-class narcolepsy therapy targeting orexin receptors.